CLLS

Cellectis (CLLS)

About Cellectis (CLLS)

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Details

Daily high

$4.26

Daily low

$3.91

Price at open

$4.25

52 Week High

$5.48

52 Week Low

$1.10

Market cap

345.3M

Dividend yield

0.00%

Volume

148,069

Avg. volume

137,219

P/E ratio

-14.37

Cellectis News